Alan Pollack
This newsletter provides a look back into a year of accomplishments, challenges, and heartfelt losses. We continue to mourn the losses of Renae and Arnee, who were so vital to our energy, promise, history, and future. We dealt with the enigma of COVID, enduring wave after wave, with what has turned into the most significant medical event in our lifetime.
What I witnessed during the past year was a team that pulled together even more and met each challenge with solutions, caring, and compassion. Helping cancer patients is at the soul of our team. And it showed in every aspect of the care we give our patients.
By every measure, we were successful. Despite the many challenges, our patients continued to compliment us for all that we do for them via another Press Ganey Pinnacle of Excellence award. New technology was thoughtfully embraced and applied. New Divisions were created to accommodate our growth. Our trainees and faculty have assumed greater roles nationally and there has been an elevation in the impact of our research.
Being a part of such an accomplished and collegial team is the best reward imaginable. Thank you for continuing to put our patients first and maintaining our unique culture during these stressful times. It is an honor to serve with you. The promise of greater success is ripe for the year ahead.
As always, we welcome your feedback and ask that you please send information about accomplishments to Felisa Flores and Roberto Manzano (and thanks to them for putting this together!).
Stay safe and healthy!
Alan Pollack, M.D., Ph.D.
Professor and Chair
|
|
|
|
Jean-Samuel Oliver Adrien, Lab Technician
Mohammad Alhusseini, Ph.D., Postdoc
Paulo Roberto Del Valle, Ph.D., Postdoc
Maytee Diaz-Williams, B.S., Proton Program coordinator
Ailyn Hernandez Garcia, M.H.S.A., Supvr. of Rad Onc Authorizations
Tim Horton, Ph.D., Postdoc
Alessandro Valderrama Cerdan, Lab Technician
|
CongratulationsResident Graduates
|
|
|
FAREWELLRADONC DEPARTURES
|
|
|
Our honoreesHonored by residents
|
|
|
|
ABR Boards: Congrats to junior faculty Dr. Ricardo Llorente, Dr. Jessica Meshman, and Dr. Benjamin Spieler, along with former resident Dr. Nirav Patel, who passed the American Board of Radiology clinical written boards exams, and to Dr. Sarah Dooley (PGY-5), who passed the Physics and Radiobiology written boards.
Dr. Anis Ahmad: Kudos on his appointment as Research Assnt. Professor.
Medical physics team--Gamma Knife Source Exchange commissioning and testing completion: Bravo, Irene Monterroso, M.Sc., who led the project, and former resident Dr. Dolla Toomeh for her hard work.
Medical physics team--Varian Ethos accelerator commissioning and testing completion: Well done, Dr. Kyle Padgett, who led the project, and resident Dr. Rodrigo Delgadillo, Irene Monterroso, M.Sc., and former resident Dr. Dolla Toomeh, for their exceptional efforts.
Our RadOnc clinic: Congratulations for receiving the 2021 Press Ganey Pinnacle of Excellence Award in patient experience. This is the third year in a row that our clinic wins the honor, which is annually awarded to top performing organizations. The award recognizes groups that have maintained consistently high levels of excellence in patient experience, engagement, or clinical quality performance.
Dr. Scott Welford: Congrats on his appointment as Radiation Oncology Biology Division Chief. He was also recently appointed to be the Assistant Director for Faculty Development at Sylvester.
|
White House invites Dr. Mahal to join new Health Equity Leaders Roundtable series.
According to a November 4 INVENTUM article by Lisette Hilton, Dr. Brandon Mahal will be both the only participant to represent oncology and the only one practicing in Florida. Dr. Mahal said that the White House wants to hear from the nation’s established and up-and-coming clinical leaders in health equity.
“We had our first meeting to discuss health equity, how it impacts our community and our institutions and what our institutions are doing to combat health care disparities," he said. "My role is to be the voice of cancer disparities and cancer health equity, and I bring that voice representing Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine.”
The White House Office of Public Engagement has asked that twice each month, 14 accomplished clinicians representing medical specialties, nursing, social work, public health, and medical education gather to offer perspectives on access to care and how to ensure all people get equitable care regardless of such factors as race, insurance, and immigration status.
“The White House wants to learn about best practices nationwide, so they can use the lessons and themes to inform policy at the highest level,” said Dr. Mahal, who is nationally known for his research in cancer disparities and community outreach and engagement. "With research I identify problems that contribute to cancer disparities and health equity issues. The reason I do that work is to look for and study solutions and I try to show where solutions may work. But ultimately, the solutions are limited without policy implementation. Now, at the highest level, I can bring my research and solutions to the White House to potentially impact national policy.”
Dr. Mahal also shared his insights about cancer disparities in a Miami Herald May 25, 2021 article by Ana Veciana-Suarez. In the story, he discusses a paradox of precision medicine, which targets the individual genetics of a patient's tumor, but risks widening the gap in survival rates between Black men and the rest of the population. “The targeted therapies we now used are designed for white of European-descendants,” Dr. Mahal said about the demographic that makes up the majority of study participants. In addition, “we know less about the genomics [of Black men’s tumors] and that directly affects how we design our treatments,” he said.
Dr. Mahal notes that African-American men with similar tumor characteristics can count on comparable outcomes when they receive the appropriate therapy. “It shows how important it is for patients to get early screening and receive timely treatment,” he adds. Researchers have yet to determine why African-American men have a higher risk of prostate cancer, but Dr. Mahal is encouraged that the convergence of big data and artificial intelligence will help physician-scientists figure out what genetic and lifestyle factors come into play. He said “we need large-scale studies across the country and across the globe to identify what factors determine [the higher prevalence of prostate cancer among Black men] and to what degree these affect outcome.”
In her article about Sylvester bringing diversity to clinical trials, in the Fall 2021 issue of University of Miami Medicine, Veciana-Suarez wrote that while Dr. Mahal was growing up in a poor community in central California, he witnessed how “cancer was universally fatal. It was a death sentence. . . But as I got into my medical training, I saw where many cancers have excellent therapies — if only patients can receive them.”
At the annual meeting of the American Society of Clinical Oncology this past summer, Dr. Mahal and his co-authors presented a study that showed Black men were less likely to be genetically profiled early. They were also less likely to be part of clinical trials. Both facts directly affect targeted treatment and outcome.
“I was drawn to Sylvester in part because of its community-oriented approach to looking at and solving health care disparity,” he said. “Other institutions are just now recognizing this, but here it has been core to the mission. Sylvester Director Stephen Nimer has a firm and thorough understanding of how important this is.”
|
|
|
His 7-year grant will identify glioblastoma patients who are failing radiation therapy during treatment.
Dr. Eric Mellon's study, “A physiologic adaptive radiation therapy pipeline for glioblastoma by daily multiparametric MRI and machine learning,” will investigate how advanced imaging during treatment may be used to improve radiation therapy for patients with glioblastoma, a deadly brain tumor, according to Richard Westlund's March 8th INVENTUM article.
“Glioblastoma is the most common cancer originating in the brain with an average survival of only 18-24 months,” Dr. Mellon said. “Our goal is to identify glioblastoma patients who are failing radiation therapy during treatment and implement aggressive second-line treatments to improve survival.”
An experienced specialist in the use of magnetic resonance imaging (MRI) for brain cancers, Dr. Mellon is the principal investigator for the study. He received the highly competitive National Cancer Institute R37 Method to Extend Research in Time (MERIT) award after his project grant scored among the best in the nation. The MERIT award provides early-stage investigators with five years of research funding and eligibility to extend their grant an extra two years.
Dr. Mellon aims to enroll 100 glioblastoma patients using MRIdian, an advanced technology developed by ViewRay, Inc., that combines daily MRI with radiation therapy. This will allow Dr. Mellon to conduct daily assessments of brain cavity caused by the surgical removal of the tumor and any unremovable tumor.
“The findings from our study will help radiation oncologists deliver the most effective personalized care for glioblastoma patients,” he said. “Our study may also have important applications for treating other types of tumors.”
|
|
|
A group of researchers led by Dr. Welford reveals new link between obesity, chemerin, and kidney cancer.
According to a March 24, 2021 article in INVENTUM, the researchers' paper, which was published Cancer Discovery last March, describes a mechanistic link in kidney cancer between fat metabolism and obesity that holds promise to be a novel renal cancer biomarker and drug target.
Dr. Scott Welford’s group hypothesized that kidney cancer and systemic fat could be talking to each other through a group of signaling proteins called adipokines; if they were, this would set up a situation where a factor in the blood could be detectable and possibly blocked to reduce cancer burden. The hypothesis turned out to be true.
The researchers found that a protein named chemerin is present in higher quantities in the blood of obese individuals and plays an essential role in controlling fat metabolism in kidney cancer cells. Furthermore, kidney cancers also produce chemerin as a way to promote themselves, and thus even higher levels can be seen in patients with kidney cancer as opposed to those without.
“There is also a possibility that the implications of the findings go beyond kidney cancer. Altered lipid biology is present in many cancers,” Dr. Welford said in the article. “We are hoping the link between obesity and cancer through chemerin can be extended to other cancers as well.”
|
|
|
Dr. Portelance and Nurse Steinhagen interviewed about self-care tips for patients.
Dr. Lorraine Portelance and Randi Steinhagen, R.N., were both interviewed for a UMiami Health News article about how to take care of yourself during radiation therapy treatment. In the Oct. 19th article by Milly Dawson, they provided helpful guidelines related to diet, dental care, remaining hydrated, getting enough sleep, and being willing to ask for the help that you need.
"To get through your course of radiation as smoothly as possible, and to receive the most benefit with the least amount of discomfort, you have to be quite careful about self-care," Dr. Portelance said. "The best predictor of how well a person will do during radiation is their general physical condition before they begin treatment."
The main thing to keep in mind is to consult your care team about problems or questions. "Don't ignore side effects, and talk about them with your doctor or a nurse. There may be adjustments that can be made to help you feel better," said Dr. Portelance, who recommended keeping a notebook. "Day by day during your treatment, keep a running, detailed list of problems or issues you're having. Include notes about your level of pain from day to day, write down how many short- or long-acting pain pills you needed.”
She suggested bringing this record to your treatment visits: "It will help your doctor make needed adjustments, based on good information, to provide you with nice pain relief all day.”
Nurse Steinhagen discussed how radiation can affect patients’ appetites.
"The effects on appetite and digestion depend on where the radiation is aimed," Nurse Steinhagen said. If the radiation is targeted towards the lower abdomen, patients may experience loose stools, diarrhea, or cramping. Aimed somewhat higher on the abdomen, it may lead to bloating and nausea.
Dr. Portelance was also interviewed for a January 2021 INVENTUM article about Sylvester’s innovative treatments for women with cervical cancer.
Cervical cancer is the third most common gynecologic malignancy in the United States. When a woman is diagnosed with early-stage cervical cancer, the first treatment is typically surgery, according to Richard Westlund’s article. “But if the cancer has progressed beyond surgery, then radiation treatment, combined with chemotherapy as needed, can deliver good outcomes,” she said.
|
|
|
NCI grant to expand Sylvester’s SURF Fellowship, directed by Dr. Rai.
The five-year grant will expand the Summer Undergraduate Research Fellowship (SURF) program, a 10-week fellowship that inspires and educates undergraduates who are considering careers in biomedical and cancer research, according to an August 6, 2021 INVENTUM article by Lisette Hilton. The program runs from mid-May through the end of July 2022.
“The NCI grant will allow us to expand and innovate the SURF program,” said Dr. Priyamvada Rai, who directs the program and is the NCI grant PI. “One of our programmatic goals has been for the SURF students to experience the world-class faculty, research, and resources at the Miller School and Sylvester, so that we can recruit them back when they go to the next level of their training.”
When Dr. Rai and colleagues looked more closely at SURF candidates, they noticed that most were interested in cancer biology, which motivated Dr. Rai to apply for NCI funding. The NCI’s R25 Comprehensive Research Experiences to Advance Training and Education (CREATE) grant will be used to expand SURF’s cancer research component by recruiting 20 cancer-focused undergraduate scholars a year.
|
|
|
Dr. Dal Pra and Dr. Mahal contributed to ASCO 2021.
According to Lisette Hilton's June 14, 2021 INVENTUM article, Dr. Brandon Mahal was among the authors of “Genomic disparities across Gleason scores” and “Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis,” at the American Society of Clinical Oncology conference last June.
Dr. Mahal and his coauthors suggest that the ancestral study represents the largest group of African American men in a genomic study defining comprehensive genetic profiling use, the genomic landscape, and therapeutic implications of comprehensive genetic profiling in prostate cancer ancestry. They found that African American men were less likely to receive genetic profiling earlier in treatment and less likely to be treated in clinical trials, which could affect the genomic landscape, outcomes, and ultimately disparities.
“Men of African ancestry experience the greatest burden of disease in prostate cancer, and this research indicates that differences in cancer outcomes and tumor genomics are strongly influenced by socioeconomic factors and structural barriers such as access to comprehensive genomic profiling and clinical trial enrollment, and not necessarily inherent differences in biology,” Dr. Mahal said.
“To ensure equitable opportunities for precision medicine, we need to expand access to and awareness of advances that impact patient care and outcomes, including timely use of genomic testing to help make informed treatment decisions,” he said.
Dr. Mahal also presented “Molecular, immunologic, and clinicodemographic landscape of MYC-amplified (MYCamp) advanced prostate cancer (PCa).”
Dr. Alan Dal Pra presented “Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).”
|
|
|
She was also part of a breast cancer expert webinar.
Dr. Cristiane Takita was interviewed for a UMiami Health News article about a national study that will help determine if proton therapy, which can provide greater accuracy and do a better job sparing normal tissue, can help protect heart health during radiation treatment.
In a John Senall article from October 2020, Dr. Takita, who is the local PI for the Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer, also known as the Radiotherapy Comparative Effectiveness (RADCOMP) consortium trial, said that this is the largest study ever to compare standard radiotherapy with proton beam therapy in breast cancer patients. More than 1,200 patients are being enrolled nationwide, including the Miami area.
"Participating patients are randomly assigned to either traditional photon radiation therapy, or to proton beam therapy. If the data shows that proton therapy for this cancer leads to equal recurrence reduction and fewer adverse cardiac events, it will establish a new national treatment guideline,” said Dr. Takita, the proton breast program leader at Sylvester.
Study participants will be monitored for at least 10 years after completing their radiation therapy. Experts will measure and compare the patients’ reported levels of fatigue, anxiety, and self-body image.
Previously, according to the Journal of the American Medical Association, researchers have reported a less than one percent average risk of a patient developing heart disease over 10 years following radiation therapy for cancer of the left breast. But that risk factor triples in patients who already had other high-risk factors for heart disease.
“Smaller studies done at individual centers have shown a significant benefit of proton beam therapy over photon beam radiotherapy for these reasons,” Dr. Takita said. “By expanding the participant base, as well as the study length, our results may help ensure the best options are made available to patients in an affordable manner.”
“We use a stepwise procedure to determine which cases are most appropriate for this therapy,” she said. “By running comparative treatment plans, our team can recommend what may be the best route of achieving radiation therapy success and sparing healthy tissue.”
Last April, Dr. Takita was also part of a panel of Sylvester experts during a free webinar on innovations in breast cancer management.
|
|
|
Dr. Dal Pra interviewed about prostate cancer patients' care options.
Dr. Alan Dal Pra discussed prostate cancer patients’ options for a February 2021 UMiami Health News article by Milly Dawson.
"Patients need to understand before they begin treatment that they have options," he said. If you have a cancer that is contained within the prostate or one that has only spread to nearby areas, your treatment may ultimately involve one or more forms of treatment including surgery, radiation, and hormone therapy, he said.
According to the American Cancer Society, roughly one in eight men will develop prostate cancer at some point. The disease is the second most frequent cancer in men, after skin cancer. It usually develops slowly, over many years, though some patients have a fast-spreading, aggressive form of the cancer. Experts predict about 249,000 new prostate cancer diagnoses and more than 34,000 deaths from the disease in 2021. About 60% of cases occur in men over age 65.
"It's important for men to know that starting active treatment right away isn't always advisable," Dr. Dal Pra said. “Many men with slow-growing, low-risk tumors can be safely monitored without any surgery or radiation, avoiding potential side effects of these treatments."
Treatments have grown more successful, tolerable and convenient. The most advanced technologies in radiation treatment are available at Sylvester, including proton therapy. "Every man's experience with prostate cancer is individual, but we are much better at estimating how a cancer at a certain stage will respond to the different forms of treatment available," Dr. Dal Pra said. "This helps patients decide how to proceed."
Cancer patients who receive multidisciplinary cancer care usually face a shorter lag between receiving their diagnosis and the start of treatment, research has shown. When a care plan grows out of discussions between doctors with different backgrounds, the plan is more likely to follow the most up-to-date guidelines and involve joining a clinical trial, which can be highly advantageous.
“Patients in clinical trials do better than other patients with similar cases for several reasons,” Dr. Dal Pra said. One reason, he explains, is the emphasis on quality assurance in clinical trials. Even if a patient is not in the group that receives a new treatment, they still receive care that adheres to the latest guidelines for quality care.
“Another reason patients do better in clinical trials is that there are so many doctors and nurses involved in their care. Every aspect of the treatment plan is checked, and triple checked. Nothing is overlooked,” he said.
|
|
|
Dr. Rai mentored a winner and Dr. Mellon presented his study at the conference.
During a virtual conference in March 2021, Dr. Alan Pollack announced Sylvester’s third cohort of Calabresi Scholars, who started the program in June. Dr. Pollack is the executive committee PI and program director for UM’s Calabresi Clinical Oncology Research Career Development Program.
Dr. Pollack was interviewed for an April 2021 INVENTUM newsletter article about the K12 Paul Calabresi Symposium by Richard Westlund. “Sylvester has one of only 22 NCI-funded K12 programs in the country,” he said. “Since launching our K12 program in 2018, we have had five faculty scholars who are well on their way to becoming leaders in patient-oriented, translational cancer research.”
“The NCI funds two scholars for two-year terms,” Dr. Pollack said. “This year, we are supporting a third scholar from our own cancer center funds as a commitment to this important program.”
Dr. Pollack introduced the three new scholars at the annual symposium, which brought together current and former scholars, former K12 scholars from other institutions, and principal investigators of K12 grants to share their experiences and formulas for success.
The three winning researchers received Paul Calabresi Career Development Awards for Clinical Oncology (PCACO) K12 from the National Cancer Institute. The winners and their projects are:
- Dr. Namrata Chandhok, assistant professor in the Division of Hematology: Exploiting Defective DNA Damage Repair in Isocitrate Dehydrogenase Mutant Acute Myeloid Leukemia and Myelodysplastic Syndrome to Develop Novel Therapeutic Strategies
- Dr. Janaki Sharma, assistant professor in the Division of Medical Oncology: Repurposing Riociguat: A Novel Therapeutic Option for Prostate Cancer (Dr. Priyamvada Rai was one of Dr. Sharma's mentors.)
- Dr. Trent Wang, assistant professor in the Division of Transplantation and Cellular Therapy: MEK Inhibition for the Prevention of Graft-Versus-Host Disease in Combination with Conventional Prophylaxis after Allogeneic Hematopoietic Cell Transplantation
At the conference, Dr. Eric Mellon was one of five current Calabresi Scholars who presented their studies: His was “Daily multiparametric MRI of glioblastoma during primary chemoradiation therapy.”
UM’s Calabresi program is a K12 whose purpose is to identify and help establish new faculty leaders in patient-oriented, clinical cancer research.
|
|
|
Dr. Freedman and Dr. Takita interviewed for article about female clinicians treating female patients.
In a Spring 2021 article in University of Miami Medicine, Dr. Laura Freedman and Dr. Cristiane Takita were interviewed by Ana Veciana-Suarez about how Sylvester’s female clinicians and researchers use their leadership roles to provide outstanding care to breast and gynecologic cancer patients and to further the knowledge of tumor biology.
As women diagnosing and treating other women, the relationship transcends that of traditional medical-professional connection to patients, Veciana-Suarez writes, and it often becomes deeper, strengthened by a healthy dose of empathy and compassion.
“As a woman treating a breast cancer patient, I can relate to issues of motherhood, hormonal changes, the change in appearance of a breast — a body part which can at times physically define a woman,” Dr. Freedman said. “I laugh with my patients as they discuss the good times and want to cry with them when there are setbacks. However, I always feel connected to their journey, as much of their journey is connected to their womanhood, something I share with them.”
Dr. Cristiane Takita said she was initially drawn into the field of radiation oncology because of her fascination with technology in cancer treatment and her wish for a strong connection with cancer patients. “I always felt that my career path gave deep meaning to my adult and professional life,” she said. “What drives me to be a game changer in my patients’ lives is my constant desire to find ways to improve the quality of their treatment while decreasing toxicity through innovative clinical trials.”
|
|
|
Two "Best Research Award" winners and a Top 5 Trainee winner were mentored by dept. faculty.
According to a UM Grad News May 2021 article, two of the 4 annual Medical Faculty Association "Best Research Award" winners were mentored by department faculty:
- Second Place: Sze Kiat Tan, Cancer Biology, whose mentor is Dr. Scott Welford. The title of Tan's dissertation is: Adipokine mediated metabolic rewiring drive clear cell renal cell carcinoma
- Third Place: Clara Troccoli, Cancer Biology, whose mentor is Dr. Priyamvada Rai. The title of Troccoli's dissertation is: Redox vulnerabilities as therapeutic targets in castration-resistant prostate cancer
In addition, Ayush Rana, a graduate student in Cancer Biology mentored by Dr. Welford, was one of five students selected by faculty reviewers for a Top Trainee award during last May's Zubrod Lecture and Awards presentation, according to a June INVENTUM article by Diana Gonzalez.
|
|
|
Dr. Punnen credits collaborators Drs. Pollack and Stoyanova after receiving endowed chair in solid tumor research.
In acknowledgement of his innovative research in prostate cancer, Dr. Sanoj Punnen was awarded the Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, according to an INVENTUM article last September by Damian McNamara. The designation allows Dr. Punnen, a urologist and urologic oncologist at Sylvester, and his team to expand the scope and influence of their work.
Dr. Punnen’s research focuses on prostate cancer detection and risk assessment. “It's about figuring out who needs to be treated and who can be safely monitored, as well as the intensity of that treatment or monitoring,” he said. “Much of my work looks at imaging and biomarkers and how they play into that risk assessment."
Dr. Punnen credited a partnership between the institution, scientists he collaborates with such as Dr. Dipen J. Parekh, the chief operating officer and chair of the Urology department, Dr. Radka Stoyanova, Dr. Alan Pollack, and philanthropic organizations.
|
|
|
|
|
1-year DOD grant awarded.
Last December, Dr. Ahmad's study, “Preventing radiation-induced podocyte injury and nephrotoxicity in renal cell carcinoma (RCC)" won a Department of Defense award.
|
|
|
|
|
SCCC Tumor Biology Program grant awarded.
Her study, "Targeting the prostate cancer immuno microenvironment,” was awarded last August.
|
|
|
|
|
Seven-year grant for glioblastoma study awarded.
Dr. Mellon's study, “A physiologic adaptive radiation therapy pipeline for glioblastoma by daily multiparametric MRI and machine learning,” was also awarded supplemental funds through a 4-year Sylvester NIH grant last April.
In addition to the grants, to support his research, through Sylvester, Dr. Mellon received a significant donation from Steven Dwoskin, in recognition of the help that he has provided to Mr. Dwoskin and his family and friends over the years.
|
|
|
|
|
NIH NCI grant awarded to advance future cancer researchers’ careers.
Dr. Rai's project, “Comprehensive research experiences to advance training and education (CREATE) for future cancer researchers" received the NIH NCI grant last July. It will innovate and expand the Summer Undergraduate Research Fellowship (SURF) program, a 10-week fellowship that inspires and educates undergraduates who are considering careers in biomedical and cancer research.
|
|
|
|
|
Dr. Scott Welford wins 5-year NIH grant and 3-year Florida Health dept. grant.
His new 5-year R01 award, announced last March, is for the study "Adipokine signaling as a therapeutically targetable driver of tumor metabolism."
In addition, Dr. Welford received renewal funding for his study, "Polyamine and glutamate driven interactions in the glioblastoma-brain microenvironment" through a 5-year NIH R01 award announced last July. Last July, he also received a five-year Sylvester NCI/NIH Immediate Grant Funding Program award that will help fund this study.
Last May, the Florida Department of Health's James and Esther King Biomedical Research Program awarded him a grant for his study, "Chemerin: a link between obesity, smoking and renal cancer."
|
|
|
|
|
Sylvester Catchment Pilot grant awarded.
Dr. Xu’s study, “Preclinical development of low intensity ultrasound to prevent paclitaxel-induced alopecia in ovarian cancer chemotherapy” received the one-year award last June.
|
|
|
EDUCATIONResearch Retreats
|
|
|
Jan. 21, 2021: Residents' Retreat
Our visiting reviewer was Dr. Rahul Tendulkar, clinical director and residency program director at the department of radiation oncology, Cleveland Clinic Cancer Center. There were presentations by:
- Dr. Rodrigo Delgadillo: “The correlation of cone beam deltaradiomics of prostate cancer patients to quality of life, genitourinary and gastrointestinal toxicities”
- Dr. Benjamin Rich: “Utility of magnetic resonance imaging in long term survivors of patients with brain metastasis treated with Gamma Knife”
- Dr. Crystal Seldon Taswell: "CivaSheet use for recurrent STS: The UM Experience"
- Dr. Benjamin O. Spieler: “Prostate cancer biomarker discovery project: Plasma exosomal mRNA analysis for patients on BLASTM and MAST protocols” and “Can radiomics predict tumor response to PD-1 checkpoint inhibitor immunotherapy in patients with advanced NSCLC?”
- Dr. Rachel Tobillo: “Female sex and increased immune marker mRNA gene expression are associated with decreased overall survival in patients with HPV-negative Head and Neck Cancer”
- Dr. Renae van Wyhe: “Mapping local recurrence and prognostic factors in patients who have undergone mastectomy for breast cancer”
|
|
|
March 17, 2021: Faculty retreat
There were presentations by:
- Dr. Eric Mellon: “Pilot trial of spectroscopic MRI-guided, dose-escalated proton radiation therapy for recurrent glioblastoma”
- Dr. Lorraine Portelance: “‘SMART TNT’: A conservative approach for locally advanced rectal cancer”
- Dr. Junwei Shi: “Theranostic gold nanoparticles for prostate cancer targeted imaging, radiosensitization, and drug delivery,” part 1
- Dr. Wensi Tao: “Theranostic gold nanoparticles for prostate cancer targeted imaging, radiosensitization, and drug delivery,” part 2
|
|
|
Sept. 22, 2021: Faculty retreat
There were presentations by:
- Dr. John Chetley Ford: “Co-clinical trials to determine the biological underpinnings of low-field MRIgRT-based radiomics”
- Dr. Priyamvada Rai: “Targeting therapy-induced senescent cells to increase the efficacy/durability of androgen deprivation therapy (ADT)”
- Dr. Scott Welford: “Mechanisms of radiation induced damage to the brain and brain tumors”
- Dr. Wensi Tao: "Antitumor and radio-sensitization effects of HDAC inhibitor Romidepsin in prostate cancer"
|
|
|
Jan. 26, 2022: Residents' Retreat
There were presentations by:
- Dr. William Jin: “HIDRATE PRO – A prospective trial evaluating a digital behavioral health intervention to improve bladder-filling in prostate cancer patients” and “Spectroscopic magnetic resonance imaging for delineation of recurrent glioblastoma”
- Dr. Chris Montoya: “Biochemical outcomes for node-positive prostate cancer treated with post-op RT with and without a simultaneous integrated nodal boost”
- Dr. Benjamin Rich: “Para-aortic radiation therapy for oligorecurrent prostate cancer”
|
|
|
Thanks to those who shared their expertise with us: Aug. 2020 - Sept. 2021.
- Nancy Lee, M.D., Radiation Oncology Dept., Memorial Sloan Kettering Cancer Center: "Towards Personalization for Nasopharyngeal and Oropharyngeal Carcinoma"
- David Palma, M.D., Ph.D., Schulich School of Medicine & Dentistry, University of Western Ontario: "Stereotactic for Metastatic Disease: Mission Accomplished, or Mission Creep?"
- Rahul Tendulkar, M.D., Radiation Oncology Dept., Cleveland Clinic Taussig Cancer Institute: "Post-Prostatectomy Radiotherapy: Beyond 2020 Vision"
|
|
|
The dept. will sponsor an annual lecture on breast cancer in her honor.
Dr. van Wyhe, a fourth post-graduate year resident in radiation oncology who passed away suddenly last July, was described by Dr. Pollack this way: "She will be deeply missed on so many levels. She was filled with compassion and caring for her patients. Her loss at such a young age and with such incredible potential to contribute to and shape patient care in our specialty and beyond is tragic."
She was a graduate of Baylor University, after which she obtained a Master’s in Business Administration at Christian Brothers University in Memphis. Dr. van Wyhe then went to Baylor College of Medicine in Houston. During medical school, she gravitated toward breast cancer research and spent a productive year working with Dr. Wendy Woodward and Dr. Michael Stauder at the MD Anderson Cancer Center.
She had been active in a number organizations, including the Society for Women in Radiation Oncology. She also had a dynamic approach to communicating via social media.Throughout her time in our residency program, she continued to pursue answers to key questions in breast cancer management, collaborating with several of our faculty members. She was driven to push the field forward.
Her family, friends, and colleagues held a memorial in her honor last July at the Louis Pope auditorium.
Starting this year, in honor of Dr. van Wyhe, the department will invite a distinguished visiting professor to deliver a talk about breast cancer every year in early July.
|
|
|
The dept. will sponsor an annual lecture on lymphoma or ocular melanoma in his honor.
Dr. Arnold Markoe, our department Chair Emeritus, who passed away last November, will be remembered as a significant figure due to his outstanding clinical and organizational skills, as well as his relentless attention to detail, wrote Joey Garcia in an InventUM story from last December. He was named clinical director during his first year in the department, followed by more than 30 years of having a significant impact in the clinic and the classroom.
Dr. Markoe, or "Arnee" to those who knew him best, was a graceful and wise leader with a kind sense of humor. He will be deeply missed.
“Arnee displayed not only an extraordinary intellect but also a compassion for people, couched in his humble and humorous outlook on life,” Dr. Aaron Wolfson said. “No matter the seriousness or gravity of a situation, Arnee also had a joke or story to tell that put everyone in the room at ease and created a safe space for optimizing outcomes for the patient and family.”
Throughout his time at the Miller School, Dr. Markoe also served as the department chair for 13 years. In the 2007–2008 academic year, the Miller School recognized him as one of the five highest-rated physicians in its patient satisfaction surveys. After he stepped down as department chair in 2008, he remained active in clinical work, serving as co-leader of the Sylvester Ocular Malignancy Site Disease Group, where he wrote papers and mentored faculty, residents, and medical students.
Even when he recently became ill, Dr. Markoe continued to see patients as much as possible, while continuing to mentor faculty and trainees. Although his passing creates a huge void in the department, his dedication and kindness will continue to resonate in the hearts and minds of many for years to come.
Dr. Pollack remembered him as a compassionate and engaged man: “Per the many notes I received about Arnee, the expressions of sadness have been intermixed with descriptions of his humor, kindness, wisdom, teaching, and welcoming approach to mentorship and advice at all levels. Arnee loved his patients, and his patients loved him. He touched every trainee and faculty member, and he never turned down an opportunity to contribute by leading or participating in key committees in the department and institution."
Dr. Wolfson, who long worked with Dr. Markoe, described him as "a mensch of the highest order." Here is how he recalled his beloved colleague:
"Arnee and I both joined the faculty of the new Department of Radiation Oncology at UM during the 1989-1990 academic year. I was fresh out of Residency and Arnee was already a national and international M.D.-Ph.D. figure in radiation oncology for ocular malignancies, lymphomatous diseases, and monoclonal antibody therapy for cancer from Dr. Luther Brady’s program at Hahnemann University Hospital (now the Drexel University College of Medicine).
"Within the first year after his arrival at Miami, Arnee was named the Clinic Director of the department. . . Even though the department was housed in the North Wing One building at Jackson Memorial Hospital, Arnee had the fledgling department seeing a hundred patients a day on three linear accelerators, with six clinical faculty members and five residents.
"He also improved the transcription service to ensure that clinic notes were dictated, corrected, signed, and placed in the hospital chart within three days after the patient visit, along with a hand-written note being placed on the hospital chart the same day. Moreover, Arnee insisted that the faculty send to each referring physician a dictated letter of each new consulted patient, including a brief history and physical exam with pertinent findings, staging of disease, and a review of literature supporting the recommended treatment plan, which was unheard of at that time for any department.
"Although Arnee always said he never desired being a Department Chair, he was the overwhelming candidate for the position when a national search was conducted in the 1995-1996 academic year. Arnee ably led the department for the next 13 years. . ."
A memorial service for Dr. Markoe was held in January via Zoom.
Starting this year, in honor of Dr. Markoe, the department will invite a distinguished visiting professor to deliver a talk about lymphoma or ocular melanoma every year in November.
|
|
|
Feb. 26, 2022
During the 12th annual event on Feb. 26, nearly 4,500 DCC participants from across the U.S. and the world raised more than $7 million, according to Richard Westlund's Feb. 28th INVENTUM article.
So far, our department team has raised $23,221; last year, our team raised $30,620. Since it launched in 2010, the DCC has raised more than $45.5 million.
On February 4th, the Dolphins Challenge Cancer (DCC) announced an expansion of its partnership with the V Foundation for Cancer Research through a $5 million commitment to support innovative cancer research at Sylvester, according to a February INVENTUM article. The V Foundation’s commitment of $500,000 a year will be matched by the DCC over the next five years, for a total of $5 million funded for critical cancer research focused on disparities.
In collaboration with the V Foundation, the DCC will work to support early career researchers and translational research at Sylvester. Sylvester researchers will be able to apply for grants in the Early Career Investigator and Translational categories, which will be awarded based on the recommendations of the V Foundation’s Scientific Advisory Committee.
|
|
|
|
- Dr. Jonathan Bell (first author, presenter): "Quantification of Target Volume Changes on Radiation Planning MRI in IDH-wildtype Glioblastoma"
- Adrian Breto (presenting author): “A Deep Learning Approach for Automated Volume Delineation on Daily MRI Scans in Glioblastoma Patients”
- Dr. Ruben Carmona (presenting and senior author): “Development and Validation of a Machine Learning-Based Predictor for OS and PFS in HPV-Negative HNSCC Patients With Microscopic ENE and Intermediate-Risk Disease” and “Destructive-Type TP53 Mutations are Independently Associated With Worse Overall Survival in Patients With HPV-Negative Head and Neck Squamous Cell Carcinoma”
- Dr. Alan Dal Pra (presenter): “Performance of a Genomic Classifier (GC) Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) After Radical Prostatectomy (RP)”
- Dr. Rodrigo Delgadillo (first and presenting author): “Cone Beam CT Based Delta-Radiomics of Prostate Cancer Patients and Their Correlation to Genitourinary Toxicities and Quality of Life”
- Dr. Tejan Diwanji (senior author): Disparities In Use Of Salvage Whole Brain Radiation Therapy Versus Salvage Stereotactic Radiosurgery After Initial Stereotactic Radiosurgery For Brain Metastases” and “Yield of Surveillance Imaging in Long-Term Survivors of Brain Metastasis Treated with Stereotactic Radiosurgery” and "Quantification of Target Volume Changes on Radiation Planning MRI in IDH-wildtype Glioblastoma"
- Dr. Nesrin Dogan (senior author): “Cone Beam CT Based Delta-Radiomics of Prostate Cancer Patients and Their Correlation to Genitourinary Toxicities and Quality of Life”
- Dr. Sarah Dooley (presenting author): “Destructive-Type TP53 Mutations are Independently Associated With Worse Overall Survival in Patients With HPV-Negative Head and Neck Squamous Cell Carcinoma”
- Jessica Fine (presenting author): “The Effect of Health Insurance on Childhood Cancer Survival in Pediatric Patients Treated With Radiation in Multi-Center Health Systems”
- Dr. John Chetley Ford (senior author): “Impact of PSMA Targeted Gold Nanoparticles on Prostate Cancer Radiation Bystander Effect” and “Predictive Ability of Delta Radiomic Texture Features (DRTF) Extracted From Liver Patients Treated With Magnetic Resonance Guided Stereotactic Body Radiotherapy (MRgSBRT)”
- Dr. Sandra Gaston (senior author): “Plasma Exosomal RNA Biomarkers of High-Risk Prostate Cancer”
- Aaron Gurayah (presenting author): “Predictors of Outcomes in Iodine-125 Brachytherapy-Treated Uveal Melanomas: A Modern Institutional Study”
- Daiki Hara (presenting author): “Impact of PSMA Targeted Gold Nanoparticles on Prostate Cancer Radiation Bystander Effect”
- Dr. Derek Isrow (senior author): “The Effect of Health Insurance on Childhood Cancer Survival in Pediatric Patients Treated With Radiation in Multi-Center Health Systems”
- Dr. William Jin (first and middle author): “Predictive Ability of Delta Radiomic Texture Features (DRTF) Extracted From Liver Patients Treated With Magnetic Resonance Guided Stereotactic Body Radiotherapy (MRgSBRT)” and “Clinical Characteristics and Post-Operative Complications as Predictors of Radiation Toxicity After Treatment With I125 Eye Plaque Brachytherapy for Uveal Melanomas” and “Predictors of Outcomes in Iodine-125 Brachytherapy-Treated Uveal Melanomas: A Modern Institutional Study”
- Nabiha Shabbir Khakoo (presenting author): “The Predictive Value of Post-Treatment PET-CT Imaging for Patients With Curable Anal Canal Cancer”
- Wendi Ma (presenting author): “The Dual Effect of the HDAC Inhibitor Romidepsin on Androgen Receptor Signaling and DNA Damage Repair in Prostate Cancer”
- Dr. Brandon Mahal (participant and presenter): “Physician Driven Social Change: A Historical Perspective and Opportunities for Radiation Oncologists” (educational session) and “Translating health disparities research into advocacy and action” (symposium)
- Dr. Eric Mellon (presenter): “Whole brain spectroscopic MRI for RT Dose Escalation in Glioblastoma” (panel) and “"Adaptive Radiotherapy of Glioblastoma with MRIdian"
- Dr. Ivaylo Mihaylov (senior author): “Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer — From Bench to Bedside”
- Dr. Chris Montoya (presenting author): “Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer — From Bench to Bedside”
- Shareen Patel (presenting author): “Survey of Oncology Providers' Attitudes and Practices in Evaluating Sexual Health in Cancer Care”
- Vanessa Ann Peters (presenting author): “Clinical Characteristics and Post-Operative Complications as Predictors of Radiation Toxicity After Treatment With I125 Eye Plaque Brachytherapy for Uveal Melanomas”
- Dr. Alan Pollack (middle and senior author): “Validation of a 22-Gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer” and “The Dual Effect of the HDAC Inhibitor Romidepsin on Androgen Receptor Signaling and DNA Damage Repair in Prostate Cancer”
- Dr. Lorraine Portelance (moderator, presenter, middle author): “Advancements in Gynecological Treatment in the Era of Personalized Medicine” and “MRI Guided External Beam Radiation for GYN Malignancies” and “Where Are We Going With Pancreatic Cancer Radiotherapy? Novel Biomarkers and Dosing Strategies” and “Patterns of Utilization and Clinical Adoption of 0.35 MR-Guided Radiation Therapy in the United States — Understanding the Transition to Adaptive, Ultra-Hypofractionated Treatments”
- Dr. Benjamin Rich (first author, presenter, middle author): “Disparities In Use Of Salvage Whole Brain Radiation Therapy Versus Salvage Stereotactic Radiosurgery After Initial Stereotactic Radiosurgery For Brain Metastases” and “Yield of Surveillance Imaging in Long-Term Survivors of Brain Metastasis Treated with Stereotactic Radiosurgery”
- Dr. Stuart Samuels (senior author): “Clinical Characteristics and Post-Operative Complications as Predictors of Radiation Toxicity After Treatment With I125 Eye Plaque Brachytherapy for Uveal Melanomas”
- Yash Sunil Soni (first author): “Disparities In Use Of Salvage Whole Brain Radiation Therapy Versus Salvage Stereotactic Radiosurgery After Initial Stereotactic Radiosurgery For Brain Metastases”
- Dr. Benjamin Spieler (presenter): “Plasma Exosomal RNA Biomarkers of High-Risk Prostate Cancer”
- Dr. Radka Stoyanova (senior author): “A Deep Learning Approach for Automated Volume Delineation on Daily MRI Scans in Glioblastoma Patients”
- Dr. Rachel Tobillo (presenting author): “Female Sex and Increased Immune Marker mRNA Gene Expression are Associated With Decreased Overall Survival in Patients With HPV-Negative Head and Neck Cancer”
- Dr. Aaron Wolfson (senior author): “The Predictive Value of Post-Treatment PET-CT Imaging for Patients With Curable Anal Canal Cancer”
- Dr. Raphael Yechieli (presenter): “Institutional Approaches to Promoting Wellness During COVID-19 and Beyond” (event panel)
|
|
|
ResearchPublications (July '20 - Dec. '21)
|
|
|
|
Ahmad A, Shi J, Ansari S, Afaghani J, Molina J, Pollack A, Merscher S, Zeidan YH, Fornoni A, Marples B. Non-invasive assessment of radiation-induced renal injury in mice. Int J Radiat Bio. 97(5): 664-674, 2021. [Epub: 2021 March 15.]
Ahmad A, Afaghani J, Shi J, Ansari S, Kim JJ, Shi Y, Merscher SM, Pollack A, Zeidan Y, Fornoni A, Marples B. Role of collagen receptors in radiation-induced nephrotoxicity. J Am Soc Nephrol. (Suppl.) 32:155, 2021 Oct.
Achard V, Dal Pra A, Zilli T. Re: Carlo A. Bravi, Nicoal Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical. Eur Urol. 78(6): e221-e222, 2020 Dec. doi: 10.1016/j.eururo.2020.09.004. [epub 2020 Sep 30.]
Ahmad A, Totiger TM, Benaduce AP, Marples B, Mihaylov IB. Establishing correlations between breast tumor response to radio-immunotherapy and radiomics from multi-parametric imaging: An animal study. App. Sci. 10(18): 6493, 2020 September 17.
Albert A, Kahn JM, Knoll MA, Lirette S, Yechieli R, Gerber NK, Jagsi R, Katz MS. Current social media use among radiation oncology trainees. Adv Radiat Oncol. 6(2): 10062, 2021 Mar-Apr. [Epub 23 December 2020.] doi: 10.1016/j.adro.2020.100642.
Amaya C, Luo S, Baigorri J, Baucells R, Smith ER, Xu XX. Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells. BMC Cancer. 21(1): 981, 2021 Sep 1. doi: 10.1186/s12885-021-08722-7.
Anderson J, Dooley S, Sim A. Training in radiation oncology: Missing leadership and advocacy development. Applied Radiation Oncology. 10 (1): 5, 2021 March 30.
Arega MA, Dee EC, Muralidhar V, Nguyen PL, Franco I, Sanford NN, Mahal BA. Mental distress and mental health services receipt in foreign-born survivors of cancer: a national health interview survey analysis. J Gen Intern Med. 36(8): 2495-2498, 2021 Aug. doi: 10.1007/s11606-020-06031-6. [Epub 2020 Aug 17.]
Bagshaw HP, Martinez A, Heidari N, Scheinker D, Pollack A, Stoyanova R, Horwitz E, Morton G, Kishan AU, Buyyounouski MK. A personalized decision aid for prostate cancer shared decision making. BMC Med Inform Decis Mak. 21(1): 374. 2021, Dec 31. doi: 10.1186/s12911-021-01732-2.
Baikovitz JB, Thornton L, Garcia-Buitrago MT, Livingstone AS, Studenski MT, Portelance L. Pathologic validation of an yttrium-90 trans-arterial radioembolization dosimetry: A case report. J. Surg. Case Rep. 2021(4):rjab078, 2021 April 30. doi: 10.1093/jscr/rjab078 [ecollection 2021 Apr.]
Barsky AR, Carmona R, Verma V, Santos PMG, Both S, Bekelman JE, Christodouleas JP, Vapiwala N, Deville C Jr. Comparative analysis of 5-year clinical outcomes and patterns of failure of proton beam therapy versus intensity modulated radiation therapy for prostate cancer in the postoperative setting. Pract Radiat Oncol. 2021 Mar-Apr;11(2):e195-e202. doi: 10.1016/j.prro.2020.11.005. [March 2021] Epub 2020 Nov 24. PMID: 33242634.
Barsky AR, Kraus RD, Carmona R, Santos PMG, Li C, Schwartz LE, Ballas LK, Vapiwala N. Investigating association of perineural invasion on prostate biopsy with Gleason score upgrading at prostatectomy: A multi-institutional analysis. Cancer Med. 9(10):3383-3389, 2020 May. doi: 10.1002/cam4.2920. 2020 May [Epub 2020 Mar 18]. PMID: 32187859; PMCID: PMC7221308.
Benveniste RJ, Yechieli R, Diwanji T. Early magnetic resonance imaging after gamma knife radiosurgery of brain metastases. World neurosurgery. 146:e1177-1181, 2021 Feb 1. doi: 10.1016/j.wneu.2020.11.119. [Epub 2020 Nov 27.]
Blessing NW, Chen Y, Choi CJ, Kanokkantapong J, Tao W, Pelaez D, Lee BW. Orbital hemorrhagic necrosis, globe rupture, and death from intraorbital injection of 1% sodium deoxycholate in a murine model. Ophthalmic Plast Reconstr Surg. 37(3S):S98-S103, 2021 May-Jun 1. doi: 10.1097/IOP.0000000000001850.
Bossart E, Mellon EA, Monterroso I, Elsayyad N, Diwanji T, Samuels S, Dogan N. Assessment of single isocenter linear accelerator radiosurgery for metastases and base of skull lesions. Physics Med. 81: 1-8, 2021 January. PMID: 33278764 [Epub 2020 Dec 3.] https://doi.org/10.1016/j.ejmp.2020.11.011
Campbell SR, Tom MC, Agrawal S, Efstathiou JA., Michalski JM, Abramowitz MC, Pollack A, Spratt DE, Hearn JWD, Stephans KL, Gao T, Jianbo L,Tendulkar RD. Integrating prostate-specific antigen kinetics into contemporary predictive nomograms of salvage radiotherapy after radical prostatectomy. Eur Urol Oncol. S2588-9311(21)00085-7, 2021 May 17. doi:10.1016/j.euo.2021.04.011 [Online ahead of print.]
Chang YC, Stoyanova R, Danilova S, Pretell-Mazzini JA, Kerr DA, Wilky BA, Subhawong T. Radiomics on radiography predicts giant cell tumor histologic response to denosumab. Skeletal Radiol. 50(9):1881-1887, 2021 Sept. doi: 10.1007/s00256-021-03752-5. Epub 2021 Mar 17.
Civantos FJ, Leibowitz JM, Arnold DJ, Stubbs VC, Gross JH, Thomas GR, Sargi Z, Casiano RR, Franzmann EJ, Weed D, Perez C, Samuels M, Goodman KW, Goodwin WJ. Ethical surgical triage of head and neck cancer patients during the COVID-19 pandemic. Head Neck. 42 (7):1423–1447, 2020 July doi: 10.1002/hed.26229. [Epub May 2021.]
Cordoni F, Missiaggia M, Attili A, Welford SM., Scifoni E, La Tessa C. Generalized stochastic microdosimetric model: The main formulation. Phys Rev E. 103(1-1):012412, 2021 Jan. doi: 10.1103/PhysRevE.103.012412. (available on 2022-01-01)
Dal Pra A, Pollack A. Using hormone therapy with salvage radiotherapy according to presalvage PSA levels. Nat Rev Urol. 17(9): 489-490, 2020 Sept. doi: 10.1038/s41585-020-0333-9.
De Ornelas M, Xu Y, Padgett K, Schmidt RM, Butkus M, Diwanji T, Luciani G, Lambiase J, Samuels S, Samuels M, Dogan N. CBCT-based adaptive assessment workflow for intensity modulated proton therapy for head and neck cancer. Int J Part Ther. 7(4): 29-41, 2021 Mar 15. doi: 10.14338/IJPT-D-20-00056.1. [ecollection Spring 2021.]
Dee EC, Mahal BA, Arega MA, D'Amico AV, Mouw KW, Nguyen PL, Muralidhar V. Relative timing of radiotherapy and androgen deprivation for prostate cancer and implications for treatment during the COVID-19 pandemic. JAMA Oncol. 6(10): 1630-1632, 2020 Oct 1. doi: 10.1001/jamaoncol.2020.3545.
Dee EC, Muralidhar V, Arega MA, Kishan AU, Spratt DE, Dess RT, King MT, Sha ST, Santos PMG, Butler SS, Sanford NN, Nguyen PL, Mahal BA. Factors influencing noncompletion of radiation therapy among men with localized prostate cancer. Int J Radiat Oncol Biol Phys. 109(5):1279-1285, 2021 Apr 1. doi: 10.1016/j.ijrobp.2020.11.064. Epub 2020 Dec 1.
Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, Kishan AU, Maurer T; GAP6 Consortium, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, Eisenberger M, Carducci M, Pienta KJ, Markowski M, Paller CJ, Antonarakis ES, Berlin A, Ost P, Tran PT. The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur Urol. S0302-2838(20)31026-5, 2021 Jan 5: doi: 10.1016/j.eururo.2020.12.040. Online ahead of print.
Delgadillo R, Ford JC, Abramowitz MC, Dal Pra A, Pollack A, Stoyanova R. The role of radiomics in prostate cancer radiotherapy. Strahlenther Onkol.196(10): 900-912, 2020 Oct. doi: 10.1007/s00066-020-01679-9. [Epub 2020 Aug 21.] PMID: 32821953.
Delgadillo R, Spieler B, Ford JC, Kwon D, Yang F, Studenski M, Padgett KR, Abramowitz MC, Dal Pra A, Stoyanova R, Pollack A, Dogan N. Repeatability of CBCT radiomic features and their correlation to CT radiomic features for prostate cancer. Med Phys. 48(5): 2386-2399, 2021 May. doi: 10.1002/mp.14787. [Epub 2021 Mar 16.]
Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR, Song DY, Sun Y, Mehra R, Kaffenberger SD, Morgan TM, Nguyen PL, Feng FY, Sharma V, Tran PT, Stish BJ, Pisansky TM, Zaorsky NG, Moraes FY, Berlin A, Finelli A, Fossati N, Gandaglia G, Briganti A, Carroll PR, Karnes RJ, Kattan MW, Schipper MJ, Spratt DE. Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging collaboration for cancer of the prostate. JAMA Oncol. 6(12):1912-1920, 2020 Oct. doi: 10.1001/jamaoncol.2020.4922.
Diwanji T, Sawant A, Sio TT, Patel NV, Mohindra P.. Proton stereotactic body radiation therapy for non-small cell lung cancer. Annals Of Translational Medicine. Ann Transl Med. 8(18):1198, 2020 Sept. 0.doi:10.21037/atm-20-2975
Dooley SA, Chaurasia A, Price JG, Jeans EB. Medical school curricula: Giving radiation oncology a seat at the table. Appl Rad Oncol. 10(2): 4, 2021 July 27.
Dooley S, Sim AJ, Campbell SR, Jeans EB, Anderson JD, Tye K, Goodman CR. Opportunities to improve radiation oncology medical education in the post-pandemic era. Int J Radiat Oncol Biol Phys. 108(2):455-457, 2020 Oct 1. doi:10.1016/j.ijrobp.2020.06.038
Dooley S, Sim AJ, Campbell SR, Jeans EB, Anderson JD, Tye K, Goodman CR. In reply to Taunk et al. Int J Radiat Oncol Biol Phys. 109(3): 835-836, 2021 March 1. doi: 10.1016/j.ijrobp.2020.10.026
Ezzati A, Studenski M, Gohari M. Spatial mesh based surface source model for the electron contamination of an 18 MV photon beam. J Med. Phys. 45(4):221-225, 2020 Oct-Dec. [epub 2021 Feb 2.] doi: 10.4103/jmp.JMP_29_20.
Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT. Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG/RTOG 9601 randomized clinical trial. JAMA Oncol. 7 (4):544-552, 2021 Apr 1. doi: 10.1001/jamaoncol.2020.7671.
Fung CY, Vapiwala N, Mattes MD, Mohindra P, Shah C, Yechieli R, Truong M-T, Sanders T, Arnone A, Royce TJ, Ennis RD. US radiation oncologists (re) defined: An American Society for Radiation Oncology scope of practice study. Int J of Radiat Oncol, Biol Phys. 109(2):335-343, 2021 Feb 1. doi: 10.1016/j.ijrobp.2020.09.029. [Epub 2020 Sep 18.]
Garcia-Soto AE, McKenzie ND, Whicker ME, Pearson JM, Jimenez EA, Portelance L, Hu JJ, Lucci JA 3rd, Qureshi R, Kossenkov A, Schwartz L, Mills GB, Maity A, Lin LL, Simpkins F. Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Cancer. 127(13):2279-2293, 2021 Jul 1; doi: 10.1002/cncr.33449. Epub 2021 May 1.
Geller JS, Allegra PR, Seldon CS, Spieler BO, Cohen LL, Barnhill SW, Huntley SR, De La Zerda A, Samuels S, Wang L, Isrow D, Wolfson AH, Yechieli RL. Primary versus secondary radiotherapy for heterotopic ossification prevention about the elbow. J Orthop Trauma. 2021 May 24. doi: 10.1097/BOT.0000000000002188. [Online ahead of print.]
Goodman CR, Sim A, Jeans EB, Anderson JD, Dooley S, Agarwal A, Tye K, Albert A, Gillespie EF, Tendulkar RD, Fuller CD, Kavanagh BD, Campbell SR. No longer a match: Trends in radiation oncology National Resident Matching Program (NRMP) data from 2010-2020 and comparison across specialties. Int J Radiat Oncol Biol Phys. 110(2): 278-287, 2021 June 1. doi: 10.1016/j.ijrobp.2021.03.006
Hara D, Tao W, Totiger TM, Pourmand A, Dogan N, Ford JC, Shi J, Pollack P. Prostate cancer targeted X-ray fluorescence imaging via gold nanoparticles functionalized with prostate-specific membrane antigen (PSMA). Int J Radiat Oncol Biol Phys. 111(1): 220-232, 2021 Sept 1. doi: 10.1016/j.ijrobp.2021.04.032. [Epub 2021 May 6.]
Hayee A, Lugo I, Iakymenko OA, Kwon D, Briski LM, Zhao W, Nemov I, Punnen S, Ritch CR, Pollack A, Jorda M, Stoyanova R, Parekh DJ, Gonzalgo ML, Kryvenko ON. Anterior or posterior prostate cancer tumor nodule location predicts likelihood of certain adverse outcomes at radical prostatectomy. Arch Pathol Lab Med. 2021 Oct 20. doi: 10.5858/arpa.2021-0104-OA. Online ahead of print.
Hu Q, Padron K, Hara D, Shi J, Pollack A, Prabhakar R, Tao W. Interactions of urea-based inhibitors with prostate-specific membrane antigen for boron neutron capture therapy. ACS Omega. 6(49): 33354-33369, 2021 Dec 1. doi: 10.1021/acsomega.1c03554. eCollection 2021 Dec 14.
Iakymenko OA, Lugo I, Briski LM, Nemov I, Punnen S, Kwon D, Pollack A, Stoyanova R, Parekh DJ, Jorda M, Gonzalgo ML, Kryvenko ON. Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers. Prostate. 81(12):866-873, 2021 Sep. doi: 10.1002/pros.24183. [Epub 2021 Jun 29.]
Iorio GC, Ricardi U, Dal Pra A. Radiation-induced lymphopenia beyond the COVID-19 pandemic. Front Oncol. 10: 617302, 2020 Nov 18. doi: 10.3389/fonc.2020.617302. eCollection 2020.
Iorio GC, Spieler BO, Ricardi U, Dal Pra A. The impact of pelvic nodal radiotherapy on hematologic toxicity: a systematic review with focus on leukopenia, lymphopenia and future perspectives in prostate cancer treatment. Crit Rev Oncol Hematol. 168:103497, 2021 Oct 16. doi: 10.1016/j.critrevonc.2021.103497. Online ahead of print.
Isrow D, Ahmadi M, Impellizzeri S, Captain B. Photochemical synthesis and radical generation of the nickel-tin dimer [Ni(SnBut3)(CNBut)2(CO)]2. J Organometallic Chem. 936, 12175, 2021 March 15. DOI: https://doi.org/10.1016/j.jorganchem.2021.121715
Jacobson GM, Takita C. Editorial: New approaches to breast cancer radiotherapy. Front Oncol. 11:645615, 2021 Feb 24. doi: 10.3389/fonc.2021.645615. [eCollection 2021.]
Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt DE. A systematic review of the evidence for the Decipher genomic classifier in prostate cancer. Eur Urol. 79(3):374-383, 2021 Mar. doi: 10.1016/j.eururo.2020.11.021. [Epub 2020 Dec 5.]
Jordan SE, Schlumbrecht M, George S, Pearson JM, Wolfson A, Slomovitz B, Portelance L, Huang, M. The Moore criteria: Applicability in a diverse, non-trial recurrent cervical cancer population. Gynecol Oncol. 157(1): 167-172, 2020 April. doi:10.1016/j.ygyno.2020.01.001. PMID: 31983517. [epub 2020 Jan 23.]
Kensler KH, Pernar CH, Mahal BA, Nguyen PL, Trinh QD, Kibel AS, Rebbeck TR. Racial and ethnic variation in PSA testing and prostate cancer incidence following the 2012 USPSTF recommendation. J Natl Cancer Inst. 113(6):719-726, 2021 June 1. djaa171. doi: 10.1093/jnci/djaa171.
Lee E, Eum SY, Slifer SH, Martin ER, Takita C, Wright JL, Hines RB, Hu JJ. Association between polymorphisms in dna damage repair genes and radiation therapy-induced early adverse skin reactions in a breast cancer population: A polygenic risk score approach. Int J Radiat Oncol Biol Phys. 106(5): 948-957, 2020 Apr 1. doi: 10.1016/j.ijrobp.2019.12.021. Epub 2020 Jan 29.
Lee JY, Gallo RA, Ledon PJ, Tao W, Tse DT, Pelaez D, Wester ST. Integrating differential gene expression analysis with perturbagen-response signatures may identify novel therapies for thyroid-associated orbitopathy. Transl Vis Sci Technol. 9(9):39, 2020 Aug 25. doi: 10.1167/tvst.9.9.39. [ecollection 2020 Aug.]
Levinson K, Beavis AL, Purdy C, Rositch AF, Viswanathan A, Wolfson AH, Kelly MG, Tewari KS, McNally L, Guntupalli SR, Ragab O, Lee YC, Miller DS, Huh WK, Wilkinson KJ, Spirtos NM, Van Le L, Casablanca Y, Holman LL, Waggoner SE, Fader AN. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecol Oncol. 162(3):532-538, 2021 Sep. doi: 10.1016/j.ygyno.2021.06.017. Epub 2021 Jul 1.
Llorente R, Spieler BO, Victoria J, Takita C, Yechieli R, Ford JC, Brown K, Samuels MA, Mellon EA. MRI-guided stereotactic ablative radiation therapy of spinal bone metastases: a preliminary experience. Br J Radiol 93: 20190655. 2020 Jan. doi: 10.1259/bjr.20190655. [Epub 2019 Nov 12.]
Mahal BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, Kantoff P, Mucci LA, Schaeffer EM, Spratt D, Yamoah K, Nguyen PL, Rebbeck TR. Racial differences in genomic profiling of prostate cancer. N Engl J Med. 383(11):1083-1085, 2020 Sep 10. doi: 10.1056/NEJMc2000069.
Mahal BA, Gerke T, Awasthi S, Soule HR, Simons JW, Miyahira A, Halabi S, George D, Platz EA, Mucci L, Yamoah K. Prostate cancer racial disparities: A systematic review by the prostate cancer foundation panel. Eur Urol Oncol. S2588-9311(21)00146-2, 2021 Aug 23. doi: 10.1016/j.euo.2021.07.006. Online ahead of print.
Matiello J, Dal Pra A, Zardo L, Silva R, Berton DC. Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer. Thorac Cancer. 11(11): 3139-3144, 2020 Nov. doi: 10.1111/1759-7714.13621. [epub Sep 21 of 2020].
Maziero D, Straza MW, Ford JC, Bovi JA, Diwanji T, Stoyanova R, Paulson ES, Mellon EA. MR-Guided radiotherapy for brain and spine Tumors. Front. Oncol. 11:626100, 2021 Mar 8. doi:10.3389/fonc.2021.626100 [ecollection 2021].
McClelland S 3rd, Petereit DG, Zeitlin R, Takita C, Suneja G, Miller RC, Deville C, Siker ML. Improving the clinical treatment of vulnerable populations in radiation oncology. Adv Radiat Oncol. 5(6):1093-1098, 2020 Aug 6. doi: 10.1016/j.adro.2020.07.018. [eCollection 2020 Nov-Dec.]
Mehta S, Ramey SJ, Kwon D, Rich BJ, Ahmed AA, Wolfson A, Yechieli R, Portelance L, Mellon EA. Impact of radiotherapy duration on overall survival in squamous cell carcinoma of the anus. J Gastrointestinal Oncology. 11(2): 277-290, 2020 April. doi: 10.21037/jgo.2020.02.09.
Mihaylov IB, Montoya C, Spieler B. Expanding clinical utilization of checkpoint inhibitors for cancer treatments necessitates the development of predictive models for immunotherapy-induced pneumonitis. BJSTR. 36(2): 28361-28362, 2021 June 4. : doi:10.26717/BJSTR.2021.36.005827
Mihaylov IB, Totiger TM, Giret TM, Wang D, Spieler B, Welford S. Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation. PLoS One. 16(8):e0255923, 2021. doi: 10.1371/journal.pone.0255923. [eCollection 2021.]
Nelson BA, Lapen K, Schultz O, Nangachiveettil J, Braunstein SE, Fernandez C, Fields EC, Gunther JR, Jeans R, Jimenez RB, Kharofa JR, Laucis A, Yechieli RL, Gillespie EF, Golden DW. The Radiation oncology education collaborative study group 2020 spring symposium: Is virtual the new reality? Int J Radiat Oncol Biol Phys.110(2):315-321, 2021 June 1. doi: 10.1016/j.ijrobp.2020.12.026. [Epub 2020 Dec 26]
Noy MA, Rich BJ, Llorente R, Kwon D, Abramowitz M, Mahal B, Mellon EA, Zaorsky NG, Dal Pra A. Levels of evidence for radiation therapy recommendations in the National Comprehensive Cancer Network (NCCN) clinical guidelines. Adv Radiat Oncol. 7(1):100832, 2021 Oct 29. doi: 10.1016/j.adro.2021.100832. eCollection 2022 Jan-Feb.
Odei BC, Seldon C, Fernandez M, Rooney MK, Bae J, Acheampong J, Ahmed A. Representation of women in the leadership structure of the US health care system. JAMA Netw Open. 4(11): e2136358, 2021 Nov 1. doi: 10.1001/jamanetworkopen.2021.36358.
Padgett KR, Simpson G, Asher D, Portelance L, Bossart E, Dogan N. Assessment of online adaptive MR-guided stereotactic body radiotherapy of live cancers. Physica Medica. 77: 54-63, 2020 Sep. doi: 10.1016/j.ejmp.2020.07.027 [Epub 2020 Aug 8.]
Padilla L, Burmeister JW, Burnett OL, Covington EL, Den RB, Dominello MM, Du KL, Galavis PE, Junell S, Kahn J, Kishore M, Mooney K, Mukhopadhyay ND, Studenski MT, Yechieli RL, Fields EC. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. Int J Radiat Oncol Biol Phys. S0360-3016(21)02619-5, 2021 Aug 8. doi: 10.1016/j.ijrobp.2021.07.1706. Online ahead of print.
Pasol J, Mellon EA, Feun LG, Gaurav SM, Diwanji TP, Komotar RJ. Unilateral fourth nerve palsy due to presumed metastatic melanoma. J Neuroophthalmol. 41(1): e134-e135, 2021 March 1. doi: 10.1097/WNO.0000000000000902.
Patel N, Rich BJ, Patel S, Watts JM, Benveniste R, Abramowitz M, Markoe A, Eichberg DG, Komotar RJ, De La Fuente M, Pasol J, Diwanji T. Emergent radiotherapy for leukemia-induced cranial neuropathies refractory to intrathecal therapy. Cureus. 13(5):e15212, 2021 May 24. doi: 10.7759/cureus.15212.
Patel N, Yu N, Koroulakis A, Diwanji T, Sawant A, Sio T, Mohindra P. Proton therapy for thoracic malignancies: a review of oncologic outcomes. Expert Rev Anticancer Ther. 21(2): 177-191, 2021 Feb. DOI: 10.1080/14737140.2021.1844567. [Epub 2021 Jan 8.]
Patel R, Zhang L, Desai A, Hoenerhoff MJ, Kennedy LH, Radivoyevitch T, La Tessa C, Gerson SL, Welford SM. Protons and high-linear energy transfer radiation induce genetically similar lymphomas with high penetrance in a mouse model of the aging human hematopoietic system. Int J Radiat Oncol Biol Phys. 108(4): 1091-1102, 2020 Nov. doi: 10.1016/j.ijrobp.2020.06.070. [Epub: 2020 Jul 4.]
Pennix T, Azzam G, Samuels SE. Successful radiation therapy for breast cancer in a patient with hereditary procoporphyria. Adv Radiat Oncol. 5(6):1384-1389, 2020 Jul 23. doi: 10.1016/j.redox.2020.101848 [ecollection Nov-Dec 2020.]
Pollack A, Chinea FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Paten VN, Wu X, Reis I, Studenski MT, Casillas J, Stoyanova R. phase i trial of mri-guided prostate cancer lattice extreme ablative dose (LEAD) boost radiation therapy. Int J Radiat Oncol Biol Phys. 107(2): 305-315, 2020 June 1. 2020. doi:10.1016/j.ijrobp.2020.01.052 [Epub 2020 Feb 19.]
Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin A-G, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin M-C, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM. Androgen deprivation therapy and pelvic lymph node treatment added to prostate bed salvage radiotherapy: The NRG Oncology/RTOG 0534 SPPORT randomized phase III trial. Lancet, In press.
Portelance L, Corradini S, Erickson B, Lalondrelle S, Padgett K, van der Leij F, van Lier A, Jürgenliemk-Schulz I. Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for gynecological cancers. Front Oncol. 11:628131, 2021 Aug 27. doi: 10.3389/fonc.2021.628131. eCollection 2021.
Press RH, Shelton JW, Zhang C, Dang Q, Tian S, Shu T, Seldon CS, Hasan S, Jani AB, Zhou J, McDonald MW. Bone marrow suppression during postoperative radiation for bladder cancer and comparative benefit of proton therapy-phase 2 trial secondary analysis. Int J Part Ther. 8(3): 1-10, 2021 Jul 6. doi: 10.14338/IJPT-21-00003.1. eCollection 2022 Winter.
Punnen S, Stoyanova R, Kwon D, Reis IM, Soodana-Prakash N, Ritch CR, Nahar B, Gonzalgo ML, Kava B, Liu Y, Arora H, Gaston SM, Castillo Acosta RP, Pra AD, Abramowitz M, Kryvenko ON, Davicioni E, Pollack A, Parekh DJ. Heterogeneity in genomic risk assessment from tissue based prognostic signatures used in the biopsy setting and the impact of magnetic resonance imaging targeted biopsy. J Urol. 205(5):1344-1351, 2021 May. doi: 10.1097/JU.0000000000001559. [Epub 2020 Dec 24.]
Ramachandran A, Fox T, Wolfson A, Banks J, Subhawong TK. Superficial fibromatosis: MRI radiomics and T2 mapping correlate with treatment response. Magn Reson Imaging. 81:53-59, 2021 Sep. doi: 10.1016/j.mri.2021.06.003. Epub 2021 Jun 9. https://pubmed.ncbi.nlm.nih.gov/34116132/
Ramey SJ, Silver B, Diaz DA, Munjal A, Mehta S, Rich B, Yechieli R, Takita C. Smoking cessation at a safety-net hospital: A radiation oncology-led quality improvement initiative. Adv Radiat Oncol. 11;5(5):1061-1065, 2020 Jun 11. doi: 10.1016/j.adro.2020.05.013. [eCollection 2020 Sep-Oct.]
Rich B, Huang J, Yang Y, Jin W, Johnson P, Wang L, Yang F. Radiomics predicts for distant metastasis in locally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma. Cancers (Basel). 13(22): 5689, 2021 Nov 14. doi: 10.3390/cancers13225689.
Rich BJ, Schumacher L-ED, Sargi ZB, Masforroll M, Kwon D, Zhao W, Rueda-Lara MA, Freedman LM, Elsayyad N, Samuels SE, Abramowitz MC, Samuels MA. Opioid use patterns in patients with head and neck cancer receiving radiation therapy: Single-institution retrospective analysis characterizing patients who did not require opioid therapy. Head Neck. ; 43(10): 2973-2984, 2021 Oct. doi: 10.1002/hed.26785. [Epub 2021 Jun 18.]
Rosenberg DM, Braunstein SE, Fields EF, Gillespie EF, Gunther JR, Jimenez RB, Yechieli RL, Golden DW. Radiation oncology education collaborative study group annual spring symposium: Initial impact and feedback. J Canc Educ. 2021 Mar 16. doi: 10.1007/s13187-021-01990-8. [Online ahead of print.]
|
|
Ruegg TA, Morse JM, Yechieli RL. Nurse-delivered telephone intervention to reduce oral mucositis and prevent dehydration. Oncol Nurs Forum. 48(2): 242-256, 2021 March 1. doi: 10.1188/21.ONF.242-256.
Schumacher LD, Dal Pra A, Hoffe SE, Mellon E. Toxicity reduction required for MRI-Guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. Br J Radiol. 93(1114): 20200028, 2020 Oct. doi: 10.1259/bjr.20200028. [Epub 2020 Aug 12.]
Scott JG, Sedor G, Scarborough JA, Kattan MW, Peacock J, G. Grass GD, Mellon EA, Thapa R, Schell M, Waller A, Poppen S, Andl G, Teer JK, Eschrich SA, Dilling TJ, Dalton WS, Harrison LB, Fox T, Torres-Roca JF. Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in NSCLC. J Thorac Oncol. 16(3): 428 - 438, 2021 Mar. doi: 10.1016/j.jtho.2020.11.008. [Epub 2020 Dec 8.]
Seldon C, Ahmed A, Laucis AM, Takita C. A leaky pipeline or a broken system? Astro.org. ASTRO Blog. 2021 April 27.
Seldon C, Lee A. Regional nodal irradiation in the setting of sentinel node biopsy. Ann Breast Surg. 2021. doi: 10.21037/abs-20-125
Seldon C, Puckett, L. Society for Women in Radiation Oncology mentorship program. ASTROnews. 28, Summer 2021.
Seldon C, Shrivastava G, Al-Awady A, Asher D, Ramey S, Fernandez M, Dooley S, Kwon D, Zhao W, Goel N, Diwanji T, Subhawong T, Trent J, Yechieli R. Variation in Management of Extremity Soft-Tissue Sarcoma in Younger vs Older Adults. JAMA Netw Open. 4(8):e2120951, 2021 Aug 2.. doi: 10.1001/jamanetworkopen.2021.20951.
Seldon C, Shrivastava G, Fernandez M, Jarboe J, Conway S, Pretell J, Freedman L, Wolfson A, Zhao W, Kwon D, Rosenberg A, Subhawong T, Trent J, Yechieli R. Pathologic response rates after neoadjuvant therapy for sarcoma: a single institution study. Cancers (Basel). 13(5):1074, 2021 Mar 3. doi: 10.3390/cancers13051074.
Seldon C, Wong W, Jagsi R, Croke J, Lee A, Puckett L. Remote mentorship in radiation oncology: Lessons to share. Adv Radiat Oncol. 6(4):100686, 2021 Mar 14. doi: 10.1016/j.adro.2021.100686. eCollection 2021 Jul-Aug.
Shi J, Hara D, Tao W, Dogan N, Pollack A, Ford JC. Reconstruction of X-Ray fluorescence computed tomography from sparse-view projections via L1-norm regularized EM algorithm. IEEE Access. 8: 211576-211584, 2020 Nov 23. 10.1109/ACCESS.2020.3039927
Shi J, Hara D, Tao W, Tulasigeri T, Marples B, Dogan N, Ford J, Pollack A. Theranostic PSMA-targeted gold nanoparticles using X-ray fluorescence imaging guided prostate tumor radiotherapy. Int J Radiat Oncol Biol Phys. (Suppl.) 108(3): S181, 2020 Nov 1. doi: https://doi.org/10.1016/j.ijrobp.2020.07.967.
Shi J, Xu K, Keyvanloo A, Udayakumar T, Ahmad A, Yang F, Yang Y. A multimodality image guided precision radiation research platform: Integrating X-ray, bioluminescence, and fluorescence tomography with radiation therapy. Int J Radiat Oncol Biol Phys. 108(4): 1063–1072, 2020 Nov 15. doi: 10.1016/j.ijrobp.2020.06.023. [Epub 2020 Jun 22.]
Simpson G, Ford, JC, Llorente R, Portelance L, Yang F, Mellon EA, Dogan N. Impact of quantization algorithm and number of gray level intensities on variability and repeatability of low field strength magnetic resonance image-based radiomics texture features. Phys Med. 80: 209-20, 2020 Dec. https://doi.org/10.1016/j.ejmp.2020.10.029 [Epub 2020 Nov 12].
Simpson G, Spieler B, Dogan N, Portelance L, Mellon EA, Kwon D, Ford JC, Yang F. Predictive value of 0.35 T magnetic resonance imaging radiomics features in stereotactic ablative body radiotherapy of pancreatic cancer: A Pilot Study. Med Phys. 47(8): 3682-90, 2020 Aug. doi: 10.1002/mp.14200. [Epub May 2020.]
Small W Jr, Bosch WR, Harkenrider MM, Strauss JB, Abu-Rustum N, Albuquerque KV, Beriwal S, Creutzberg CL, Eifel PJ, Erickson BA, Fyles AW, Hentz CL, Jhingran A, Klopp AH, Kunos CA, Mell LK, Portelance L, Powell ME, Viswanathan AN, Yacoub JH, Yashar CM, Winter KA, Gaffney DK. NRG Oncology/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer: An update. Int J Radiat Oncol Biol Phys. 109(2):413-424, 2021 Feb 1. doi: 10.1016/j.ijrobp.2020.08.061. Epub 2020 Sep 6.
Smith DH, Raslan S, Samuels MA, Iglesias T, Buitron I, Deo S, Daunert S, Thomas GR, Califano J, Franzmann EJ. Current salivary biomarkers for detection of human papilloma virus-induced oropharyngeal squamous cell carcinoma detection. Head Neck. 2021 July 31. doi: 10.1002/hed.26830. Online ahead of print.
Smith ER, Leal J, Amaya C, Li B, Xu XX. Nuclear Lamin A/C expression is a key determinant of paclitaxel sensitivity. Mol Cell Biol. 41(7):e0064820, 2021 June 23. doi: 10.1128/MCB.00648-20. [Epub 2021 Jun 23]
Snider JW, Molitoris J, Shyu S, Diwanji T, Rice S, Kowalski E, Decesaris C, Remick JS, Yi B, Zhang B, Hall A, Hanna N, NG VY, Regine WF. Spatially fractionated radiotherapy (GRID) prior to standard neoadjuvant conventionally fractionated radiotherapy for bulky, high-risk soft tissue and osteosarcomas: Feasibility, safety, and promising pathologic response rates. Radiat Res. 194(6):707-14, 2020 Oct. doi: 10.1667/RADE-20-00100.1.
Snider JW, Nichols EM, Mutaf YD, Chen S, Molitoris J, Diwanji T, Becker SJ, Feigenberg SJ., Reproducibility of a novel, vacuum‐assisted immobilization for breast stereotactic radiotherapy. J Appl Clin Med Phys. 22(3):8-15, 2021 March. https://doi.org/10.1002/acm2.13127. [Epub 2021 Mar 3.]
Spieler BO, Samuels SE, Llorente R, Yechieli R, Ford JC, Mellon EA. Advantages of radiotherapy simulation with 0.35 Tesla MRI for stereotactic ablation of spinal metastases. Pract Radiat Oncol. 10(5): 339-44, Sep-Oct 2020. doi: 10.1016/j.prro.2019.10.018. [Epub 2019 Nov 26.]
Studenski MT, Delgadillo R, Xu Y, Both J, Padgett K, Abramowitz M, Ford JC, Dal Pra A, Pollack A, Dogan N. Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. Phys Med. 77:154-159, 2020 Sep. doi: 10.1016/j.ejmp.2020.08.008. [Epub 2020 Aug 28.]
Studenski MT, Markoe A, Samuels SE, Correa ZM, Bossart E, Harbour JW. Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry. Brachytherapy. S1538-4721(21)00109-4, 2021 Jun 28. doi: 10.1016/j.brachy.2021.05.013. Online ahead of print.
Sunoqrot MRS, Selnæs KM, Sandsmark E, Nketiah GA, Zavala-Romero O, Stoyanova R, Bathen TF, Elschot M A. Quality control system for automated prostate segmentation on T2-weighted MRI. Diagnostics (Basel).10(9): 714, 2020 Sep 18. doi: 10.3390/diagnostics10090714.
Swami N, Hwang WL, Guo JA, Hoffman H, Abramowitz MC, Elbakouny Z, Beltran H, Chipidza F, Choueiri T, Pra AD, Huang F, Kaochar S, Kantoff P, Kim DW, Kishan AU, Kobetz E, Marinac C, Mucci LA, Muralidhar V, Pollack A, Sanford NN, Schaeffer EM, Spratt DE, Zhao SG, Rebbeck TR, Nguyen PL, Feng FY, Mahal BA, Alshalalfa M. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet. 258-259: 61-68, 2021 Nov. doi: 10.1016/j.cancergen.2021.08.004. Epub 2021 Aug 28.
Tan SK, Mahmud I, Fontanesi F, Puchowicz M, Neumann CKA., Griswold AJ, Patel R, Dispagna M, Ahmed HH, Gonzalgo ML, Brown JM, Garrett TJ, Welford SM. Obesity-dependent adipokine chemerin suppresses fatty acid oxidation to confer ferroptosis resistance. Cancer Discov. 11(8): 2072-2093, 2021 Aug. [Epub 2021 Mar 23.] doi: 10.1158/2159-8290.CD-20-1453.
Tan SK, Welford SM. Lipid in renal carcinoma: Queen bee to target? Trends in Cancer. 6(6):448-450, 2020 June. [Epub 2020 Mar 17.] doi: 10.1016/j.trecan.2020.02.017
Thakur VS, Welford SM. Generation of a conditional mutant knock-in under the control of the natural promoter using CRISPR-Cas9 and Cre-Lox systems. PLoS One. 15(10):e0240256, 2020 Oct 2. doi: 10.1371/journal.pone.0240256. eCollection 2020.
Thielhelm TP, Goncalves S, Welford S, Mellon EA, Bracho O, Estivill M, Brown C, Morcos J, Ivan ME, Telischi F, Fernandez-Valle C, Dinh CT. primary vestibular schwannoma cells activate p21 and RAD51-associated DNA repair following radiation-induced DNA damage. Otol Neurotol. 2021 Aug 20. doi: 10.1097/MAO.0000000000003322. Online ahead of print.
Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Dal Pra A, Mahal BA, Morgan TM, Mehra R, Kaffenberger S, Salami SS, Kane C, Pollack A, Den RB, Berlin A, Schaeffer EM, Nguyen PL, Feng FY, Spratt DE. Performance of clinicopathologic models in men with high risk localized prostate cancer: Impact of a 22-gene genomic classifier. Prostate Cancer Prostatic Dis. 23(4):646-653, 2020 Dec. doi: 10.1038/s41391-020-0226-2. [epub Mar 2020].
Tse BC, Dvoriantchikova G, Tao W, Gallo RA, Lee JY, Ivanov D, Tse DT, Pelaez D. Mitochondrial targeted therapy with elamipretide (MTP-131) as an adjunct to tumor necrosis factor inhibition for traumatic optic neuropathy in the acute setting. Exp Eye Res. 199:108178, 2020 Oct; doi: 10.1016/j.exer.2020.108178. [Epub 2020 Aug 3.]
Tse JD, Moore R, Meng Y, Tao W, Smith ER, Xu XX. Dynamic conversion of cell sorting patterns in aggregates of embryonic stem cells with differential adhesive affinity. BMC Dev Biol. 21(1): 2, 2021 Jan 6; doi: 10.1186/s12861-020-00234-0.
Wang C, Padgett KR, Su MY, Mellon EA, Maziero D, Chang Z. Multi-parametric MRI (mpMRI) for treatment response assessment of radiation therapy. Med Phys. 2021 Aug 10. doi: 10.1002/mp.15130. Online ahead of print.
Williamson CW, Sirák I, Xu R, Portelance L, Wei L, Tarnawski R, Mahantshetty U, Heide ES, Yashar CM, McHale MT, Bosch W, Lowenstein J, Saenz CC, Plaxe S, Eskander R, Einck J, Mundt AJ, Mayadev J, Mell LK; INTERTECC study group. Positron emission tomography-guided bone marrow-sparing radiation therapy for locoregionally advanced cervix cancer: Final results from the XXX Phase II/III Trial. Int J Radiat Oncol Biol Phys. S0360-3016(21)02707-3, 2021 Aug 19. doi: 10.1016/j.ijrobp.2021.08.019. Online ahead of print.
Wright CM, Lee DY, Shimunov D, Carmona R, Barsky AR, Sun L, Cohen RB, Bauml JM, Brody RM, Basu D, Rassekh CH, Chalian AA, Newman JG, Rajasekaran K, Weinstein GS, Lukens JN, Lin A, Swisher-McClure S. Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery. Oral Oncol. 121:105509, 2021 Aug 30. doi: 10.1016/j.oraloncology.2021.105509. Online ahead of print.
Xu Y, Diwanji T, Brovold N, Butkus M, Padgett KR, Schmidt RM, King A, Dal Pra A, Abramowitz M, Pollack A, Dogan N. Assessment of daily dose accumulation for robustly optimized intensity modulated proton therapy treatment of prostate cancer. Phys Med. 81:77-85, 2021 Jan. [Epub 2021 Jan 11.] DOI: 10.1016/j.ejmp.2020.11.035 .
Xu Y, Brovold N, Cyriac J, Bossart E, Padgett K, Butkus M, Diwanj T, King A, Dal Pra A, Abramowitz M, Pollack A, Dogan N. Assessment of knowledge-based planning for prostate intensity modulated proton therapy. Int J Part Ther. 8 (2):62-72, 2021 Jun 15. doi: 10.14338/IJPT-20-00088.1. eCollection 2021 Fall.
Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel transcriptomic interactions between immune content and genomic classifier predict lethal outcomes in high-grade prostate cancer. Eur Urol. S0302-2838(20)30939-8, 2020 Dec 7: doi: 10.1016/j.eururo.2020.11.038. [Online ahead of print.]
Yechieli R, Bialick S, Seldon C, Jonczak. Adjuvant therapies in metastatic bone disease. Operative techniques in orthopaedics. 31 (3), 100899, 2021 Sept.
Yechieli RL, Mandeville HC, Hiniker SM, Bernier-Chastagner V, McGovern S, Scarzello G, Wolden S, Cameron A, Breneman J, Fajardo RD, Donaldson SS. Rhabdomyosarcoma. Pediatr Blood Cancer. (Suppl. 2) 68: e28254, 2021 May. doi: 10.1002/pbc.28254.
Zavala-Romero O, Breto AL, Xu IR, Chang YC, Gautney N, Dal Pra A, Abramowitz MC, Pollack A, Stoyanova R. Segmentation of prostate and prostate zones using deep learning: A multi-MRI vendor analysis. Strahlenther Onkol. 196(10): 932-942, 2020 Oct. [epub Mar 2020] doi:10.1007/s00066-020-01607-x
Zhang E, Wang LS, Shaikh TS, Handorf EA, Wong JK, Hoffman JP, Reddy S, Cooper HS, Cohen SJ, Dotan E, Meyer JE. Neoadjuvant chemoradiation impacts the prognostic effect of surgical margin status in pancreatic adenocarcinoma. Ann Surg Oncol. 2021 Jun 10. doi: 10.1245/s10434-021-10219-3. [Online ahead of print.]
Zhang L, Misiara L, Samaranayake GJ, Sharma N, Nguyen DM, Tahara Y, Kool ET, Rai R. OGG1 co-inhibition antagonizes the tumor-inhibitory effects of targeting MTH1. Redox Biology. 40:101848, 2021 April. doi: 10.1016/j.redox.2020.101848. Epub 2021 Jan 2.
Zheng S, Tao W. Identification of novel transcriptome signature as a potential prognostic biomarker for anti-angiogenic therapy in glioblastoma multiforme. Cancers (Basel). 12(9):2368, 2020 Aug 21. doi:10.3390/cancers12092368.
Zheng S, Tao W. Targeting Cullin-RING E3 ligases for radiosensitization: From NEDDylation inhibition to PROTACs. Front Oncol. 10:1517, 2020 Aug 21. doi:10.3389/fonc.2020.01517. [ecollection 2020.]
|
|
